

Table of contents

Welcome address	2
Committees	3
• Executive committee	3
• Local scientific committee	3
• International scientific committee	3
• Congress secretariat	3
Introduction to the scientific programme	4
• Plenary sessions	4
• Workshops	4
• Meet the expert sessions	4
• Free Communications	4
• Integrated symposia	4
• Publication only	4
• Poster sessions	4
• Business Meetings	4
• Abstracts	4
Instructions for authors	5
• Oral presentations	5
• Poster presentations	5
• Information for session chairs	5
Scientific programme	6
Social programme	18
Tours & excursions	19
Registration	22
• Registration desk	22
• Registration fee	22
• Name badge	22
• What is included in the registration fee	22
• Congress dinner	22
• Cancellation	22
Hotel accommodation	23
General information	23
• Location – Athens	23
• Climate	23
• Timing	24
• CME accreditation	24
• Congress language	24
• Cloakroom	24
• Exhibition	24
• Insurance	24
• Internet corner	24
• Messages	24
Exhibitor catalogue	25
Late abstracts	26
• W03.1: Proteomic profile during Candida albicans infection	26
• W04.1: Molecular taxonomy and diagnostics	27
• Integrated symposium: Astellas	28
Exhibition floor plan	32

Welcome address

Dear Friends and Colleagues,

It is a great honour and pleasure for us that you have decided to attend the 4th Congress on Trends in Medical Mycology (TIMM-4).

TIMM-4 is the fourth in the series of TIMM mycological international meetings organised jointly by the European Confederation of Medical Mycology (ECMM) and by the Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (IDG-EORTC). TIMM has become one of the most important meetings in the field of fungal infections a forum in which investigators and clinicians from all over the world exchange research results and opinions on medical practice. Well-known speakers discuss the most important advances in basic science and clinical research in mycology.

Athens is the most important classical city in Greece, the birthplace of democracy, science and philosophy. Athens is full of historical and cultural treasures throughout the downtown area and the surrounding region. Acropolis with Parthenon, many other classical monuments and a great number of beautiful Byzantine churches as well as excellent museums including the newly opened marvelous Museum of Acropolis make the visitors' experience unforgettable. Greece undoubtedly will give an irresistible background for this exciting scientific forum, providing not only a beautiful setting for a high powered meeting, but also a flavour of the Greek taste of life to all congress participants.

The scientific programme includes plenary sessions on fungal infections in both immunocompromised and immunocompetent hosts led by an internationally renowned faculty giving plenary talks, round table sessions, and meet-the-expert meetings. The poster session will encourage one-to-one discussions between faculty, presenters and delegates. The meeting is designed for infectious disease specialists, haematologists, oncologists, transplant physicians, microbiologists, immunologists, dermatologists, intensivists and others with interest in medical mycology.

The TIMM-4 in Athens will once again offer excellent science and medicine in a superb venue. We are happy to welcoming all of you to the beautiful city of Athens.

George Petrikos, Emmanuel Roilides, Maiken Cavling Arendrup, Johan Maertens
TIMM-4 Executive committee

Committees

Executive committee

George Petrikkos
Emmanuel Roilides
Maiken Cavling Arendrup
Johan Maertens

Local scientific committee

Emmanuel Roilides, Thessaloniki
George Petrikkos, Athens
Despoina Devliotou-Panagiotidou, Thessaloniki
Athanasios Fassas, Thessaloniki
Efi Frangouli, Athens
Helen Giamarellou, Athens
Elma Koumantaki-Mathioudaki, Athens
Aggeliki Mitroussia-Ziouva, Athens
Ourania Nikolatou-Galiti, Athens
Helen Sambatakou, Athens
George Samonis, Heraklion
Argiris Symeonidis, Patras

International scientific committee

Murat Akova, Turkey
Thierry Calandra, Switzerland
Maiken Cavling Arendrup, Denmark
Catherine Cordonnier, France
Andreas Groll, Germany
Elisabeth Johnson, UK
Dimitrios Kontoyiannis, USA
Cornelia Lass-Flörl, Austria
Johan Maertens, Belgium
Jacques Meis, The Netherlands
Juan-Luis Rodriguez-Tudela, Spain
Claudio Viscoli, Italy
Marianna Viviani, Italy

Congress secretariat

Congress Care
P.O. Box 440
5201 AK 's-Hertogenbosch
The Netherlands
Tel +31-73- 690-1415
Fax +31-73- 690-1417
info@congresscare.com
www.congresscare.com



Introduction to the scientific programme

Plenary sessions

No session will be held in parallel to these sessions. Plenary sessions are to be recognised by the prefix: **PS**.

Workshops

Each day workshops will convene renowned speakers from several continents, who will cover a wide range of recent developments in their fields. Workshops are to be recognised by the prefix: **W**.

Meet the expert sessions

The audience will actively participate in these small sessions. Meet the expert sessions are to be recognised by the prefix: **M**.

Free Communications (Oral presentations)

These sessions are composed out of the best submitted abstracts. Free Communications are to be recognised by the prefix: **O**.

Integrated symposia

Symposia organised and sponsored by the industry. Integrated symposia are to be recognised by the prefix: **IS**.

Poster sessions

The posters are located in the Thalia and Hesperides pre-function areas. The poster exhibition is open to all participants during the entire congress. The numbers on the poster boards correspond with the abstract numbers in the abstract supplement of *Mycoses*. All authors of poster number P001 to P150 will be present at their poster on Monday 19 October 2009 from 11.00 to 12.00 hrs. All authors of poster number P151 to P335 will be present at their poster on Tuesday 20 October 2009 from 11.00 to 12.00 hrs. All posters are indicated by the prefix: **P**.

Business Meetings

Sunday 18 October 2009

10.00 - 12.00 ECOMM Council Meeting

Room: *Erato ABC*

Monday 19 October 2009

07.00 - 09.00 EORTC ID Group Meeting

Room: *Santorini 4-6*

Abstracts

All accepted abstracts as well as abstracts of invited speakers (where available) have been referenced and published in a supplement of *Mycoses*.

Instructions for authors and chairs

Oral presentations

The meeting rooms are equipped with computers and data projectors. Please bring your presentation on memory stick or CD-ROM to the central preview room on the ground floor in the Terpsichore C room latest in the break before the start of your session.

Technicians will assist you loading your presentation. It is not allowed to use your own laptop, meet the expert presenters excepted. Please make sure your presentation is suitable for IBM PC (no Macintosh). The conference programme is very tight, with not much free time between sessions.

Please respect the allotted time for presentation to ensure that your session stays on track. Reserve 5 minutes for discussion in your presentation. Arrive at the location ten minutes before the session starts. Become familiar with the operation of the audiovisual equipment. Greet the chairs who will explain how they would like to run the session.

Poster presentations

All poster boards are situated in the Thalia and Hesperides pre-function areas. The poster exhibition is open to all participants during the entire congress. The numbers on the poster boards correspond with the abstract numbers in the abstract book. All authors of poster number P001 to P150 must be present at their poster on Monday 19 October 2009 from 11.00 to 12.00 hrs. All authors of poster number P151 to P335 must be present at their poster on Tuesday 20 October 2009 from 11.00 to 12.00 hrs. Authors should be present at their poster during the assigned poster session. Your material can be attached to the poster panel with pins or tape supplied by the organisation.

Poster mounting:

Sunday 18 October from 12.00 - 19.15 hrs. and on

Monday 19 October from 08.00 - 10.00 hrs.

Poster removal:

Tuesday 20 October after 16.15 hrs. Posters that have not been removed by the author by Wednesday 12.00 hrs. are removed and disposed.

Information for session chairs

Thank you for accepting to chair a session at TIMM-4. Your contribution is very important to ensure that sessions run smoothly, and to stimulate discussion. The conference programme is very tight, with not much free time between sessions. Part of your contribution as a chair will be to ensure that your session stays on track. We kindly ask you to arrive in the room ten minutes before the session begins. Become familiar with the operation of the audiovisual equipment. Greet the authors and explain them how you would like to run the session.

The meeting rooms are equipped with computers and data projectors. The presenters are asked to bring their presentation on memory stick or CD-ROM to the central preview room Terpsichore C, latest in the break before the start of the session. Technicians will assist chairs and presenters in the meeting room. It is not allowed to use own laptops, meet the expert presenters excepted.

Scientific Programme

Sunday 18 October 2009

10.00-12.00
Erato A+B+C

ECMM Council Meeting

12.00-13.15
Terpsichore A+B

Plenary session 1

Epidemiology: Do we know who gets what, why and when?

Chairs: D.W. Warnock (USA), M.C. Arendrup (Denmark)

12.00 PS1.1 Overview: methodology and pitfalls
D.W. Warnock (USA)

12.30 PS1.2 *Candida*
M.C. Arendrup (Denmark)

12.45 PS1.3 *Aspergillus*
D.W. Denning (UK)

13.00 PS1.4 *Zygomycetes*
G. Petrikkos (Greece)

13.15-13.30
Time to switch rooms

13.30-15.00

Workshops 1-4

Workshop 1
Terpsichore A+B

Diagnostic issues for clinicians

*Chairs: P. Donnelly (The Netherlands),
H. Giamarellou (Greece)*

13.30 W01.1 Imaging findings in neutropenic vs non-neutropenic patients
C.P. Heussel (Germany)

13.50 W01.2 New developments and challenges in diagnostics
O. Marchetti (Switzerland)

14.10 W01.3 PCR – where have we gone?
M. Cuenca Estrella (Spain)

14.30 W01.4 Therapeutic drug monitoring in antifungal therapy:
why, when, how?

R.J.M. Brüggemann (The Netherlands)

14.50
Discussion

Workshop 2
Hesperides

Lungs as target of fungi and treatment

Chairs: W. Meersseman (Belgium), S.A. Papiiris (Greece)

13.30 W02.1 Fungal infections in COPD
W. Meersseman (Belgium)

13.50 W02.2 Fungal infections in LTX and CF
E. Castagnola (Italy)

14.10 W02.3 Surgical treatment: for whom and when?
G. Massard (France)

- 14.30 W02.4 Intrapulmonary drug disposition, PD interactions of antifungal drugs with pulmonary host cells
R.E. Lewis (USA)
- 14.50 Discussion

Workshop 3
Erato A+B+C

Large scale analysis in the host-pathogen interaction

Chairs: C. Gil (Spain), T. Walsh (USA)

- 13.30 W03.1 Proteomic profile during *Candida* infection
C. Gil (Spain)
- 13.50 W03.2 Genome-wide responses of *Candida albicans* to host stimuli
A. Brown (UK)
- 14.10 W03.3 Genomic analysis during *A. fumigatus* infection
T. Walsh
- 14.30 W03.4 Functional genomics in *Histoplasma*
C. Rappleye (USA)
- 14.50 Discussion

Workshop 4
Santorini 4-6

Uncommon and emerging fungal pathogens

Chairs: O. Lortholary (France), G. Samonis (Greece)

- 13.30 W04.1 Molecular taxonomy and diagnostics
S. de Hoog (The Netherlands)
- 13.50 W04.2 In vitro susceptibility of uncommon and emerging fungal pathogens to antifungal drugs
J. Meletiadis (Greece)
- 14.10 W04.3 Experimental pathogenesis and virulence
D. Kontoyiannis (USA)
- 14.30 W04.4 Options for treatment in patients
O. Lortholary (France)
- 14.50 Discussion

15.00-15.15 *Time to switch rooms*

15.15-16.45
Hesperides

**Integrated symposium 1 –
sponsored by Merck Sharp & Dohme**

In pursuit of better outcomes: considerations and the impact of new recommendations and data

Chair: P. Donnelly (The Netherlands)

- 15.15 Introduction
P. Donnelly (The Netherlands)
- 15.20 IS1.1 Practical consideration for diagnosing and treating suspected IFD in hematological patients
J. Maertens (Belgium)

- 16.00 IS1.2 European reaction to the IDSA candidiasis guidelines
T. Calandra (Switzerland)
- 16.20 IS1.3 Virulence of FKS resistant strains of *Candida* and *Aspergillus* and the implications
D. Kontoyiannis (USA)
- 16.40 Closing remarks
P. Donnelly (The Netherlands)

17.00-18.30
Hesperides

Integrated symposium 2 – sponsored by Pfizer
Latest developments in managing and preventing invasive fungal infections

Chair: T. Calandra (Switzerland)

- 17.00 Introduction
T. Calandra (Switzerland)
- 17.05 IS2.1 Candins: From the laboratory to clinical practice
C. Rotstein (Canada)
- 17.30 IS2.2 Voriconazole in IFI – primary prophylaxis: Results from the latest clinical trials
D. Marks (United Kingdom)
- 17.50 IS2.3 Voriconazole in IFI – secondary prophylaxis: Results from the latest clinical trials
C. Cordonnier (France)
- 18.10 Panel discussion & concluding comments
T. Calandra (Switzerland)

18.30-18.45 *Time to switch rooms*

18.45-19.15
Terpsichore A+B

Opening ceremony

Chairs: M. Arendrup (Denmark), J. Maertens (Belgium), G. Petrakos (Greece), E. Roilides (Greece)
Official opening

19.15-19.45
Terpsichore A+B

E. Drouhet lecture

Translational research in medical mycology: diagnosis, treatment and prevention of life-threatening mycoses
T. Walsh (USA)

19.45 **Welcome reception**

Monday 19 October 2009

07.00-09.00

Santorini 4-6

EORTC ID Group Meeting

09.00-10.00

Terpsichore A+B

Plenary session 2

The role of PK/PD in choosing antifungal drug dosing strategies

Chairs: W. Hope (UK), S. Miyakis (Greece)

09.00

PS2.1

The impact of PK/PD on antifungal treatment.
Which drug to choose?

A. Novelli (Italy)

09.30

PS2.2

Assess optimal PK/PD characteristics of antifungal agents
W. Hope (UK)

10.00-10.15

Coffee break

10.15-11.00

Hesperides

Meet the expert

M01

Antifungal serology

P. Verweij (The Netherlands), J. Maertens (Belgium)

Erato A+B+C

M02

Fungal sinusitis

A. Skiada (Greece), A. Chakrabarti (India)

Santorini 4-6

M03

Animal models

N.P. Wiederhold (USA), P. Warn (UK)

Thalia 4

M04

Case presentations

E. Mylonakis (USA), K.A. Sepkowitz (USA)

Santorini 1

M05

Educational resources on the internet

M. Richardson (UK), A.Y. Sergeev (Russia)

11.00-12.00

Thalia pre-function

Hesperides pre-function

Poster session

12.00-14.15

Lunch break

12.15-13.45

Terpsichore A+B

Integrated symposium 3 - sponsored by Schering-Plough

Successful implementation and continuance of antifungal prophylaxis in clinical practice

Chair: R.F. Duarte (Spain)

12.15

Introduction

R.F. Duarte (Spain)

12.25

IS3.1

Implementing antifungal prophylaxis into clinical practice

R.F. Duarte (Spain)

12.50

IS3.2

Monitoring patients receiving antifungal prophylaxis into clinical practice

S. Agrawal (UK), S. J. Vinnicombe (UK)

13.25 Panel discussion & concluding comments
R.F. Duarte (Spain)

14.15-15.45 Workshops 5-7 and Free Communications 1

Workshop 5 *Terpsichore A+B*

Approaches to prophylaxis and targeted treatment

Chairs: J. Maertens (Belgium), T. Calandra (Switzerland)

- 14.15 W05.1 Prophylaxis, empirical, pre-emptive therapy in presumed aspergillosis in hematological patients: Which strategy?
G. Maschmeyer (Germany)
- 14.35 W05.2 Prevention of invasive fungal infections in solid organ transplant recipients: Universal or targeted prophylaxis?
P. Grossi (Italy)
- 14.55 W05.3 Use of polyene aerosols for prophylaxis
J. Maertens (Belgium)
- 15.15 W05.4 Antifungal prophylaxis vs therapy 2009 in ICU: If, when and how
T. Calandra (Switzerland)
- 15.35 Discussion

Workshop 6 *Hesperides*

Molecular mycology/taxonomy

Chairs: S. de Hoog (The Netherlands), S. Bretagne (France)

- 14.15 W06.1 Role of molecular methods in diagnosis
S. Bretagne (France)
- 14.45 W06.2 Potential impact of new developments in the molecular identification of fungi
A. Borman (UK)
- 15.15 W06.3 Molecular typing vs traditional identification for epidemiological surveillance
Pro: F. Odds (UK) – Con: D.W. Warnock (USA)

Workshop 7 *Erato A+B+C*

Travel and immigration related mycosis

Chairs: B. Dupont (France), J.F.G.M. Meis (The Netherlands)

- 14.15 W07.1 Endemic mycoses (*Histoplasma*, *Coccidioides*, *Paracoccidioides*, *Blastomyces*, *P. marneffeii*)
R. Sjam (Indonesia), R. Wahyuningsih (Indonesia)
- 14.35 W07.2 Mycetoma / Chromoblastomycosis
J. Afeltra (Argentina)
- 14.55 W07.3 African histoplasmosis
B. Dupont (France)
- 15.15 W07.4 Other tropical mycoses
R.J. Hay (UK)
- 15.35 Discussion

Santorini 4-6

- 14.15 O1.1 Azole containing agar plates as a screening tool for azole resistance of *Aspergillus fumigatus*
J.W.M. van der Linden (The Netherlands)
- 14.30 O1.2 Discrimination of germ tube positive yeasts with a DNC Chip
G. Haase, (Germany)
- 14.45 O1.3 Multiple sequence alignments of oligonucleotides used for diagnostics of invasive aspergillosis. How to choose the right primers and probes?
M. Lengerova (Czech Republic)
- 15.00 O1.4 Identification of human pathogenic *Candida* species by MALDI-TOF mass spectrometry
O. Petrini (Switzerland)
- 15.15 O1.5 Can the 2D-DIGE proteomic approach contribute to improve the diagnosis of invasive aspergillosis?
A.F. Fekkar (France)
- 15.30 O1.6 Prospective evaluation of novel real-time PCR assays for detection of invasive candidosis and aspergillosis in comparison to antibody and antigen detection
B. Willinger (Austria)
- 15.45-16.15 Coffee break

16.15-17.45

Workshops 8-10 and Free Communications 2

Workshop 8

Terpsichore A+B

- 16.15 W08.1 Brain infection by fungi: three orders, three syndromes
M. Ruhnke (Germany)
- 16.35 W08.2 Endocarditis
P. Muñoz (Spain)
- 16.55 W08.3 Bone and joint infections
G. Petrikkos (Greece)
- 17.15 W08.4 Urinary tract infections
C. Kauffman (USA)
- 17.35 Discussion

Focal fungal infections

Chairs: M. Ruhnke (Germany), G. Petrikkos (Greece)

Workshop 9

Hesperides

- 16.15 W09.1 Dermatophytosis of skin and hair in children
E. Sotiriou (Greece)
- 16.35 W09.1 Onychomycosis
M. Schaller (Germany)
- 16.55 W09.3 Recurrent vulvovaginal candidiasis
J. Sobel (USA)

Superficial fungal infections

Chairs: R.J. Hay (UK), N. Stavrianeas (Greece)

17.15 W09.4 Onychomycosis: More than nail changes
J. Szepietowski (Poland)
17.35 Discussion

Workshop 10
Erato A+B+C

Environmental mycology

Chairs: M. Richardson (UK), R. Samson (The Netherlands)

16.15 W10.1 The association between environment and fungal disease
M. Richardson (UK)
16.35 W10.2 Climate changes and IFI
R. Samson (The Netherlands)
16.55 W10.3 Role of molecular typing in tracking fungal outbreaks
C. Klaassen (The Netherlands)
17.15 W10.4 What is the role of LAF in preventing IFI?
P. Gastmeier (Germany)
17.35 Discussion

Santorini 4-6

Free communications 2

16.15 O2.1 Interaction of antifungal agents with human platelet function
in vitro
A.H. Groll (Germany)
16.30 O2.2 Predisposing factors for colonization with *Scedosporium*
apiospermum in CF patients
S.D. Doudounakis, (Greece)
16.45 O2.3 Forty-one cases of invasive zygomycosis from a global clinical
registry
M.J.G.T. Rüping (Germany)
17.00 O2.4 Effectiveness of a regimen including a prophylaxis with
voriconazole to prevent early-onset invasive aspergillosis in
lung transplant recipients
F. Mattner (Germany)
17.15 O2.5 *Aspergillus spp.* and other moulds in air way samples from
Danish cystic fibrosis patients
K.L. Mortensen (Denmark)
17.30 O2.6 Therapeutic drug monitoring of voriconazole in pediatric patients
J.W.M. van der Linden (The Netherlands)

18.00 - 19.30

Terpsichore A+B

Integrated symposium 4 - sponsored by Gilead

IS4.1 **The Gilead Debate: this house believes there is still a role
for empirical antifungal therapy**

18.00 *Chair: F. Odds (UK)*
Proposer: R. Barnes (UK)
Seconder: K. Theunissen (Belgium)
Opposer: F. Menichetti (Italy)
Seconder: N. Blijlevens (The Netherlands)

19.30

Dinner sponsored by Gilead

Only for participants who attended integrated symposium 4

Tuesday 20 October 2009

09.00-10.00

Terpsichore A+B

Plenary session 3

Fungi related allergic syndromes

Chairs: D.W. Denning (UK), N. Sifakas (Greece)

09.00 PS3.1 Allergic bronchopulmonary aspergillosis
A. Shah (India)

09.30 PS3.2 Fungal asthma
D.W. Denning (UK)

10.00-10.15

Break

10.15-11.00

Hesperides

M06 Achievements in molecular diagnostics – blood and tissues
L White (UK), R. Bialek (Germany)

Erato A+B+C M07 New approaches to susceptibility testing of fungi
S. Arikan (Turkey), E. Johnson (UK)

Santorini 4-6 M08 Invasive fungal infections in the intensive care unit
L Klingspor (Sweden), S. Geroulanos (Greece)

Thalia 4 M09 IFI in transplant patients – TRANSNET experience
P.G. Pappas (USA), A. Symeonidis (Greece)

Santorini 1 M10 Classical mycology methods versus non-culture methods: the old versus the new
M. Petrou (UK), A. Borman (UK)

11.00-12.00

Thalia pre-function

Hesperides pre-function

Poster session

12.00-14.15

Lunch break

12.15-13.45

Hesperides

Integrated symposium 5 - sponsored by Astellas

Key questions in managing fungal infections in the hospital

Chair: D. Denning (UK)

12.15 Introduction
D. Denning (UK)

12.25 IS5.1 Critically ill patients – whom to treat and when – Interactive roundtable discussion
A. Ullmann (Germany)

12.50 IS5.2 Managing invasive candidiasis in reality: optimising the dose – Interactive roundtable discussion
J. Mouton (The Netherlands)

13.15 IS5.3 Candida biofilms and their role in infection – Interactive roundtable discussion
M. Ghannoum (USA)

13.40 Concluding remarks
D. Denning (UK)

14.15-15.45 Workshops 11-13 and Free Communications 3

**Workshop 11
Terpsichore A+B**

Antifungal resistance and treatment strategies

Chairs: D. Sanglard (Switzerland), C. Lass-Flörl (Austria)

- 14.15 W11.1 In vitro cross-resistance between azoles: a reason for concern in the clinic?
For *Aspergillus*
E. Mellado (Spain)
For *Candida*
D. Sanglard (France)
- 14.45 W11.2 Echinocandin drugs resistance
G. Garcia-Effron (USA)
- 15.00 W11.3 New insights into polyene resistance
C. Lass-Flörl (Austria)
- 15.15 W11.4 Combination therapy
F. Barchiesi (Italy)
- 15.30 Discussion

**Workshop 12
Hesperides**

Iatrogenic risk factors in the non-neutropenic patient

Chairs: C. Viscoli (Italy), A. Fassas (Greece)

- 14.15 W12.1 In the Haematological population
O. Cornely (Germany)
- 14.35 W12.1 Immunosuppression in patients with non-malignant diseases
G. Daikos (Greece)
- 14.55 W12.3 Foreign bodies and biofilms
M. Ghannoum (USA)
- 15.15 W12.4 Do we need to re-think antifungal prophylaxis in high-risk patients?
A.J. Ullman (Germany)
- 15.35 Discussion

**Workshop 13
Erato A+B+C**

Top ten papers:

Illustrating achievements and setting new goals

Chairs: E. Johnson (UK), R. Herbrecht (France)

- 14.15 W13.1 Diagnosing fungal infections
E. Johnson (UK)
- 14.45 W13.2 Treating fungal infections
R. Herbrecht (France)
- 15.15 W13.3 Basic research
N. Osherov (Israel)

Santorini 4-6

- 14.15 O3.1 Azoles and echinocandins interact with innate immune response against *Candida* spp. biofilms
A. Chatzimoschou (Greece)
- 14.30 O3.2 Direct detection of multi-azole resistant *Aspergillus fumigatus* in brain tissue
S. Camps (The Netherlands)
- 14.45 O3.3 Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation
M.J.G.T. Rüping (Germany)
- 15.00 O3.4 Pharmacodynamics of posaconazole in a neutropenic animal model of invasive pulmonary aspergillosis
A.H. Groll (Germany)
- 15.15 O3.5 Comparison of neutropenic and non-neutropenic murine models of invasive pulmonary aspergillosis following aerosolized inoculation
N.P. Wiederhold (USA)
- 15.30 O3.6 Reduced incidence of pneumonia and invasive pulmonary aspergillosis after introduction of posaconazole prophylaxis – data from the cologne aml cohort
J.J. Vehreschild (Germany)
- 15.45-16.15 Coffee break

16.15-17.45

Workshops 14-16 and Free Communications 4

Workshop 14 Erato A+B+C

Health economics (pros & cons)

Chairs: N. Maniadas (Greece), O. Cornely (Germany)

- 16.15 W14.1 Diagnosis versus prophylaxis
C. Viscoli (Italy) versus R. de Vries (The Netherlands)
- 17.00 W14.2 Cheap versus expensive antifungals
F. Menichetti (Italy) versus H. Ostermann (Germany)

Workshop 15 Hesperides

Invasive fungal infections in neonates and children

Chairs: E. Roilides (Greece), A.H. Groll (Germany)

- 16.15 W15.1 Epidemiology of fungal infections in pediatric hosts
T. Zaoutis (USA)
- 16.35 W15.2 Antifungal PK/PD in neonates and children
A.H. Groll (Germany)
- 16.55 W15.3 Neonates – approaches to prophylaxis and treatment
E. Roilides (Greece)
- 17.15 W15.4 Primary immunodeficiencies and fungal infections
A. Warris (The Netherlands)
- 17.35 Discussion

Workshop 16	Preventing and treating IFI: What's on the horizon?
Terpsichore A+B	<i>Chairs: G. Petrikkos (Greece), J. Burnie (UK)</i>
16.15	W16.1 Antifungals in the pipeline <i>P.G. Pappas (USA)</i>
16.35	W16.2 mAbs to fungal species <i>J. Burnie (UK)</i>
16.55	W16.3 Radiolabeled antibodies in the treatment of fungal infections <i>E. Dadachova (USA)</i>
17.15	W16.4 Adoptive antifungal immunotherapy <i>T. Lehrnbecher (Germany)</i>
17.35	Discussion

Santorini 4-6

Free Communications 4

16.15	O4.1 CSP typing in multi-azole resistant <i>Aspergillus fumigatus</i> isolates <i>S.M.T. Camps (The Netherlands)</i>
16.30	O4.2 In vitro-in vivo correlation for posaconazole and voriconazole against aspergillosis <i>E.M. Mavridou (The Netherlands)</i>
16.45	O4.3 Amphotericin B, voriconazole and caspofungin activity against <i>Aspergillus fumigatus</i> in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) diffusion system simulating human pharmacokinetics <i>J. Meletiadis (Greece)</i>
17.00	O4.4 Candidemia in pediatric patients in a german tertiary-care hospital: a 10-year study <i>A. Tragiannidis (Greece)</i>
17.15	O4.5 Usefulness of environmental fungal surveillance in the prevention of invasive aspergillosis in haematology patients <i>R. Reboux (France)</i>
17.30	O4.6 Ongoing semi-national surveillance of fungaemia in Denmark: have we cracked the curve? <i>M.C. Arendrup (Denmark)</i>

18.00-18.45

Terpsichore A+B

Ben De Pauw Lecture

Sponsored by Gilead Sciences

Chairs: G. Petrikkos (Greece), J. Maertens (Belgium),

Discovery and development of antifungal drugs: a reality check
F. Odds (UK)

18.45-19.00

Departure buses to Congress Dinner

Wednesday 21 October 2009

09.00-10.00

Terpsichore A+B

Plenary session 4

Host – pathogen interaction: host response

Chairs: E. Roilides (Greece), W.J. Murphy (USA)

- 09.00 PS4.1 Immunotherapy for fungal infections in the immune compromised individual: what cells/cytokines should we target?
W.J. Murphy (USA)
- 09.20 PS4.2 Innate immune response; Update
B.J. Kullberg (The Netherlands)
- 09.40 PS4.3 *Candida* affects the cytoskeleton of macrophages
E. Segal (Israel)

10.00-10.15

Coffee break

10.15–11.00

Hesperides

Meet the expert

- M11 Trauma and burns
M. Akova (Turkey), H. Sambatakou (Greece)
- Erato A+B+C M12 GI as a portal of entry for fungi
G. Samonis (Greece), O. Nicolatou-Galiti (Greece)
- Santorini 4-6 M13 Usefulness of the laboratory for the management of cryptococcosis
F. Dromer (France), M. Viviani (Italy)
- Thalia 4 M14 Management of catheter/biofilm related infections
M. Ghannoum (USA), C. Antachopoulos (Greece)
- Santorini 1 M15 Case presentations
B.J. Kullberg (The Netherlands), J.F.G.M. Meis (The Netherlands)

11.00-12.00

Terpsichore A+B

Plenary session 5

Transatlantic viewpoints (us and them)

Chairs: M.C. Arendrup (Denmark), D. Kontoyiannis (USA)

- 11.00 PS5.1 EUCAST versus CLSI. Antifungal susceptibility testing
J.L. Rodriguez-Tudela (Spain), M. Ghannoum (USA)
- 11.30 PS5.2 ECIL versus IDSA guidelines. Trends in the management of invasive fungal infections
C. Cordonnier (France), P.G. Pappas (USA)
- 12.00 Closing

Social Programme

All registered TIMM-participants:

Sunday 18 October 2009 19.30 hrs.

*Welcome reception at the Hilton Athens.
(included in the registration fee)*

Tuesday 20 October 2009 18.45-19.00 (departure) - 23.00 hrs.

*Congress dinner at the Vorres Museum.
Costs: EUR 125*

An old estate near the new Athens Airport is the site of the Vorres Museum. One of the museum's two collections contains objects of traditional folk art, pottery, rugs, antique furniture, paintings and many centuries-old items used in everyday life along with some archaeological finds. The second collection contains splendid works of modern art, consisting of paintings and sculptures created by Greek artists in the second half of the 20th century. An additional draw of the museum are the splendid gardens. In this beautiful atmosphere the congress dinner will be held.

Please note: you have to register in advance for the congress dinner. Please check for availability at the registration desk.

All registered accompanying persons:

(Registration fee EUR 150)

Sunday 18 October 2009 19.30 hrs.

Welcome reception at the Hilton Athens.

Tuesday 20 October 2009 18.45 - 19.00 hrs. departure

Congress dinner at the Vorres Museum.



Registration

Registration desk

The registration and information desk is situated on the ground floor in the Terpsichore pre-function area. The registration and information desk will be open:

Sunday 18 October	08.00 - 19.30 hrs.
Monday 19 October	08.00 - 18.00 hrs.
Tuesday 20 October	08.00 - 18.00 hrs.
Wednesday 21 October	08.00 - 12.00 hrs.

Registration fee

	After 15 Sept 2009 and on-site
ECMM / EORTC- members	EUR 995
Non-members	EUR 1195
Physicians/scientists in training*	EUR 525
Day registration	EUR 425
Accompanying persons	EUR 150
Congress dinner	EUR 125

* *Physicians/scientists in training have to provide a written certification by head of department.*

Name badge

Access to all scientific events and to the exhibits is only possible with your personal name badge, which you will receive upon registration. All participants are requested to wear their name badges during the entire congress. EUR 30 will be charged for replacement of a lost badge.

What is included in the registration fee?

Admission to the meeting, welcome reception, programme, supplement of Mycoses, certificate of attendance, 2 lunches and all coffee breaks.

The registration fee for accompanying persons includes:

Welcome reception and congress dinner on Tuesday

Congress dinner Tuesday

Dinner tickets (EUR 125 for delegates), please check for availability at the registration desk.

Cancellation

Cancellations and refund requests must be submitted in writing to the congress secretariat. Cancellations made before 1 July 2009 will be refunded less 30% to cover administration costs. After this date no refunds will be given. All refunds will be made after the congress.



Hotel accommodation

The hotel booking service agency GOLDAIR Congress is officially appointed by the organisation.

Please contact GOLDAIR Congress directly for any questions regarding hotel accommodation and tours at the Goldair information desk. Or at:

GOLDAIR Congress

Ms. Maria Ntente

15, Panepistimiou Str., 105 64 Athens - Greece

Tel. +30-210-3274570

Fax +30-210-3311021

e-mail: congress@goldair.gr

General Information

Location

TIMM-4 will be held in the Hotel Hilton Athens located in the heart of Athens. The Hilton Athens faces the spectacular Acropolis on one of the city's most fashionable avenues and served as the official IOC headquarters hotel of the 2004 Olympic Games. Museums, the concert hall and shopping areas are on walking distance of the Hilton. The Hilton Athens has an excellent underground/train connection with Athens airport and the airport bus stops in front of the hotel. Athens airport serves hundreds of flights daily from all international airlines.



Address Hilton Athens

46 Vassilissis Sofias Avenue

Athens, Greece 11528

Tel: +30-210-7281000

Fax: +30-210-7281111

CME accreditation

The congress 4th Trends in Medical Mycology (TIMM-4) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

TIMM-4 is designated for a maximum of 18 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association (AMA) towards the Physician's Recognition Award (PRA).

To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

Congress language

The Congress language will be English. No simultaneous translation will be available.

Cloakroom

A cloakroom to keep your coats is next to the registration desk at the Terpsichore and Hesperides pre-function areas.

Exhibition

The exhibition will be open during the following times:

Sunday 18 October	11:00 - 20:30
Monday 19 October	09:30 - 18:00
Tuesday 20 October	09:30 - 18:00
Wednesday 21 October	09:30 - 12:30

Insurance

In registering for the 4th Trends in Medical Mycology, delegates agree that neither the organisation nor the congress agency Congress Care is responsible for individual medical, travel or personal insurance. Delegates are requested to make their own travel and health insurance. The organisers cannot assume liability for changes in the programme due to external circumstances.

Internet corner

Two computers with free internet access are available in the Terpsichore pre-function area. Wifi internet access can be purchased at the Hilton Business Centre.

Messages

You may leave and collect messages at the registration desk during opening hours.



Tours & Excursions

An attractive choice of guided tours has been prepared for individual delegates and accompanying persons. Please note you have to register separately for these tours. Below you will find a short description. Tour prices include transfer by a modern, airconditioned bus and entrance fees.

You can book the following tours, at the desk of Goldair.

Athens Sightseeing

Half-day morning tour: 08.45 - 12.15 hrs

A good opportunity to see the centre of the city. Constitution Square (Syntagma), the House of Parliament, the Memorial to the Unknown Soldier and the National Library. Driving down Herod Atticus Street, you will see the Evzones in their picturesque uniform and the Presidential Palace. On your way to the Acropolis you will see the Hadrian's Arch, visit the Temple of Olympian Zeus and you will make a short stop at the Panathenaic Stadium where the first Olympic Games of the modern era were held in 1896. On the Acropolis visit the architectural masterpieces of the Golden Age of Athens: the Propylaea, the Temple of Athena Nike, the Erechtheion and finally "the harmony between material and spirit", the monument that "puts order in the mind", the Parthenon.

Price: EUR 50 per person

Athens by night

Evening tour: 20.15 - 00.30 hrs.

Your evening will start with a drive to Piraeus and its natural harbors, such as lively Zea with its busy yacht marina and tiny Mikrolimano, one of the most picturesque corners of Piraeus. Then, return to Athens for dinner in Plaka, the old city, in a typical Greek tavern with folk music and dancers.

Price: EUR 58 per person (drinks are not included)

Cape Sounion in the afternoon

Half day afternoon tour: 14.30 - 18.30 hrs.

Drive along the coastal road, passing the wonderful beaches of Glyfada, Vouliagmeni & Varkiza to the most Southern point of Attica, Cape Sounion, where the white marble pillars of the Temple of Poseidon stand. On the way, you have a splendid view of the Saronic Gulf and the little islands offshore. After visiting the Temple of Poseidon, you have time to walk at leisure on the rocky promontory of Sounion.

Price: EUR 38 per person

Delphi one day

Full day tour: 08.45 - 19.00 hrs.

Drive through the fertile plain of Beotia, crossing the towns of Thebes connected with the tragedy of King Oedipus – Levidia and Arachova (short stop on the way back). Arrive at Delphi, the centre of Ancient World – the “Omphalos” (Navel of Earth) – whose prestige extended far beyond the boundaries of the Hellenic World. On the slopes of Mount Parnassus, in a landscape of unparalleled beauty and majesty, lie the ruins of the Sanctuary of Apollo Pythios. Visit the Treasury of the Athenians, the Temple of Apollo and the Museum containing such masterpieces of Ancient Greek sculpture as the bronze Charioteer and the famous athlete Aghias. Lunch in the modern village of Delphi, return to Athens by the same route.

Price: Including lunch EUR 90 per person

Without lunch EUR 80 per person

Argolis one day

Full day tour: 08.45 - 19.00 hrs.

Leave by the coastal road along the Saronic Gulf to the Corinth Canal, which connects the Aegean Sea with the Ionian Sea, (short stop). Drive to Mycenae, the Homeric city of Atreides, the city “rich in gold” of the ancient poets. Visit the Lion’s Gate, the Cyclopean Walls, and the Royal Tombs e.t.c. Depart for Nauplion through the fertile plain of Argolis, the picturesque town nestling at the foot of a cliff crowned by the mighty ramparts of the Palamidi Fortress (short photo stop), leave for Epidaurus, to visit the Theatre (4th century B.C.) famous for its astonishing acoustics. Return to Athens by the National road connecting Epidaurus with Corinth. Lunch in Mycenae.

Price: Including lunch EUR 90 per person

Without lunch EUR 80 per person

Ancient Corinth half day

Half day morning tour: 08.45 - 14.00 hrs. (approximately)

Leave Athens and drive South West until we reach the Corinth Canal which connects the Aegean Sea with the Ionian Sea (short stop). Drive on and visit the ancient town of Corinth where St. Paul lived and preached for two years. The remains of the City, which include the Agora (market place) and Apollo’s Temple (6th century B.C.) clearly show how rich and important Corinth was in Ancient Times. A short stop at the Site of the Ancient Port of Cehries, where St. Paul disembarked, will conclude the visit. Return to Athens in time for lunch.

Price: EUR 55 per person

One day Cruise to HYDRA – POROS - AEGINA

Full day tour: 08.00 - 19.15 hrs. (approximately)

In the morning we take you by bus, from Athens to Piraeus for your embarkation to the cruise boat. At 08.30 depart to Hydra, where we arrive at 11.45. Here you have free time for a walk or a swim. At 13.30 embarkation and sail for Aegina past through Poros and seashore of Peloponnese. The lunch will be served during the voyage. At 15.30 we arrive at Aegina where you have time for a swim. Optional excursion, by bus, to the fine preserved Temple of Afea Athena. At 18.00 return to Athens.

Price: EUR 95 per person

Exhibitor catalogue

AdvanDX

"AdvanDx is a leading provider of fast, accurate and easy-to-use in vitro molecular diagnostic products that advance the prevention, diagnosis and treatment of bacterial infections. AdvanDx's products and services enable dramatic improvements in patient care and outcomes while reducing hospital costs".

Astellas

"Bring innovation and hope to the treatment of infectious diseases requires focus and commitment. With active research and development programmes advancing therapies for serious fungal and bacterial infections, we will continue our commitment to this field as we strive to deliver pioneering treatments to address the needs in this complex area".

Merck Sharp & Dohme

CANCIDAS® (caspofungin) I.V. offers a broad range of coverage against indicated fungal infections, has demonstrated safety and efficacy profiles in both adult and pediatric patients, and has over 9 million patient therapy days. Number calculated using number of vials sold since 2001.



W03.1 Proteomic profile during *Candida albicans* infection

C.Gil

Complutense University, Madrid, Spain

Better clinical biomarkers for invasive candidiasis (IC), a major cause of morbidity and mortality in hospitalized patients, are needed to improve early diagnosis, estimate patient outcome, predict response to a specific therapy, and monitor disease progression, among others. We postulated that the study of the *Candida* immunome (the subset of the proteome targeted by the immune system) during different host-fungus interactions by immunoproteomics and bioinformatics might offer a promising tool for discovering potential diagnostic, prognostic, predictive and monitoring biomarkers for IC.

To address this hypothesis, different immunoproteomic studies (based on 2-DE followed by Western blotting using human sera and mass spectrometry) in conjunction with multivariate statistical analyses were undertaken to individually screen and compare the serum profiles of IgG antibodies to *Candida albicans* cell wall and/or cytoplasmic proteins (i) in IC patients and non-IC subjects, (ii) in IC survivors and IC nonsurvivors, (iii) in IC responders and IC nonresponders to a specific antifungal therapy (amphotericin B and/or fluconazole), and (iv) along the course of IC (1-3).

Seven cell wall-associated proteins (including -1,3-glucosyltransferase and glycolytic enzymes) and 42 different housekeeping intracellular proteins (diverse chaperones, heat shock proteins, glycolytic enzymes, fermentative proteins, other metabolic enzymes, elongation factors, ribosomal proteins, porins and redox enzymes, among others) of *Candida albicans* were characterized as specific targets of the human IgG antibody response to IC at an early stage. Serum IgG antibodies to a large panel of *C. albicans* proteins, particularly to Bgl2p, Eno1p, Pgk1p, Pcd11p, Tkl1p and Met6p, were found to be among the most important candidates for biomarkers predicting prognosis and treatment outcomes in IC patients. Furthermore, a remarkable rise in anti-Eno1p IgG antibody levels along the course of IC correlated with good prognosis, whereas a strong increase in expression of IgG antibodies to Ssb1p, Pgk1p and Met6p was associated with fatal outcomes.

In conclusion, our immunoproteomic approaches have led to the identification of a relatively high number of clinical biomarkers for diagnosis, prognosis, selecting appropriate antifungal therapy, and monitoring of IC. These findings are being validated in a multicenter study.

This work was supported by Comisión Interministerial de Ciencia y Tecnología (BIO 2006-198), Fundación Ramón Areces, Comunidad de Madrid (DeRemicrobiana) and Instituto de Salud Carlos III (REIPI).

W04.1

Molecular taxonomy and diagnostics: developments in validation, barcodes and detections

G.S. de Hoog

CBS-KNAW Fungal Biodiversity Centre, Utrecht, The Netherlands

Molecular biology has revolutionized taxonomy. At higher levels, phylogenetic relationships between fungi frequently appear very different from what we thought them to be. Even members of a single species may prove to be unrelated. For example, environmental and clinical strains previously referred to as *Ramichloridium obovoideum* are now known to be members of widely different orders. At the downside, this inevitably leads to a proliferation of new genera and species, and to nomenclatural confusion. But on the other hand, molecular species are ecologically and clinically consistent: the clinical strains of *R. obovoideum* represent the host-specific brain pathogen *Rhinocladiella mackenziei*. Many severe opportunists have phenetically identical sibling species, which have lower virulence or may even lack pathogenicity. Validation of species circumscriptions by reference material, the type strain, is absolutely essential. Establishment of species borderlines and intraspecific variability by multilocus studies is a tedious process, which will require a lot of effort for many years to come. In the new online databases for sequence-based identification provided by CBS the criteria for reliable identification using barcodes are fulfilled. Novel diagnostics methods using these data will be presented.

IS5

Integrated symposium: Astellas Key questions in managing fungal infections in the hospital

D.W. Denning¹, A.J. Ullmann², J.W. Mouton³, M.A. Ghannoum²

¹Director, National Aspergillosis Centre, University Hospital of South Manchester, Manchester, UK, ²Johannes Gutenberg Medical School, University of Mainz III, Medizinische Klinik und Poliklinik, Mainz, Germany, ³Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands, ⁴Director, Center for Medical Mycology, Department of Dermatology, University Hospitals Case Medical Center, Cleveland, USA

Invasive fungal diseases remain a difficult challenge in the critically ill patient population with high mortality observed particularly when treatment is delayed.^{1,2}

When antifungal therapy is initiated within 24 hours of drawing the first positive blood culture, mortality is substantially lower.³

There has been a significant focus on the development and implementation of new techniques to enable early antifungal therapy in critically ill patients. Questions remain over the usefulness of the integration of risk factors into clinical predicative rules as a means of deciding when to introduce pre-emptive antifungal therapy.^{4,5} Recently, tests that detect *Candida*, either by PCR of DNA or fungal-specific antigens, have been developed.^{5,6} Though PCR holds great promise as a sensitive and potentially rapid diagnostic test, patient selection for testing remains challenging in everyday practice. Therefore, identification of patient sub-populations at the highest risk of *Candida* infections is a key challenge in clinical practice.

The emergence of non-albicans *Candida* species within the ICU, especially with reduced susceptibility to fluconazole,² has increased the importance of echinocandins, which are thought to benefit non-neutropenic critically ill patients with candidaemia or invasive candidiasis.^{3,7-12} Some data support superior outcomes of echinocandin therapy even for fully fluconazole-susceptible organisms.¹²

The clinical efficacy of the echinocandins can best be predicted using the AUC/MIC ratio which relates to the concentration-dependent killing and prolonged post antifungal persistent effect of each agent.¹³ MIC breakpoints for echinocandins are yet to be confirmed. The CLSI MIC distribution data currently support a breakpoint of ≤ 2 $\mu\text{g/ml}$ for all the echinocandins in *Candida* spp.;¹⁴ recent data on micafungin MICs obtained using the EUCAST method will be presented.¹⁵

That the echinocandins have the dose flexibility to facilitate increased concentrations should the MIC increase is highly likely. The linear PK of micafungin¹⁶ demonstrates that with increased dose, the total dose delivered to the patient rises proportionately, facilitating concentration-dependent killing. Should the dose need to be increased, sufficient drug will be delivered to counter infection without evidence of an increased incidence of dose-related adverse events.¹⁷

Nosocomial infections also cause significant morbidity and mortality in hospitalised patients.¹⁸ Central venous catheters are responsible for many such infections, most of which can be traced to biofilm formation.¹⁹ Although recommended, catheter removal is not always feasible. Therefore, agents that are effective against *Candida* biofilms are needed.

Monotherapy with the echinocandins, rather than in combination with antifungal triazoles, is effective against *Candida* biofilms.^{20–23} Data are emerging which demonstrate the *in vitro* efficacies of echinocandin catheter lock solutions on *Candida albicans* biofilm growth. For example, micafungin (5 mg/mL) substantially maintained the inhibition of metabolic activity of young and mature biofilms of *Candida albicans*.²³ Echinocandins may, therefore, offer a viable clinical option in the management of catheter-associated biofilm infections.

Echinocandins have an important role in the treatment of critically ill patients infected with *Candida* spp., and the large randomised studies of micafungin in candidaemia support its use as primary therapy.

References

1. Leon C, Ruiz-Santana S, Saavedra P et al. *Crit Care Med* 2009;37:1624–33.
2. Garey KW, Rege M, Pai MP et al. *Clin Infect Dis* 2006;43:25–31.
3. Guery BP, Arendrup MC, Auzinger G et al. *Intensive Care Med* 2009;35:206–14.
4. Paphitou NI, Ostrosky-Zeichner L, Rex JH. *Med Mycol* 2005; 43:235–43.
5. Playford EG, Eggimann P, Calandra T. *Curr Opin Infect Dis* 2008;21:610–9.
6. Mean M, Marchetti O, Calandra T. *Crit Care* 2008;12:204–12.
7. Pappas PG, Kauffman CA, Andes D et al. *Clin Infect Dis* 2009;48:503–35.
8. Gafter-Gvili A, Vidal L, Goldberg E et al. *Mayo Clin Proc* 2008;83:1011–21.
9. Kuse ER, Chetchotisakd P, da Cunha CA et al. *Lancet* 2007;369:1519–27.
10. Mora-Duarte, Betts R, Rotstein C et al. *NEJM* 2002;347:2020–9.
11. Pappas PG, Rotstein CM, Betts RF et al. *Clin Infect Dis* 2007;45:883–93.
12. Reboli AC, Rotstein C, Pappas PG et al. *N Engl J Med* 2007;356:2472–82.
13. Andes D, Dickema DJ, Pfaller MA et al. *In vivo* PD characterization of anidulafungin in a neutropenic murine candidiasis model. *Antimicrob Agents Chemother* 2008;52:539–550.
14. Garcia-Effron BG, Park S, Perlin DS. *Antimicrob Agents Chemother* 2009; 53:112–122.
15. Mouton JW, Curfs-Breuker I, Geersten E et al. Abstract presented at TIMM 2009
16. MYCAMINE SPC. Last updated 11 Nov 2008. www.emc.medicines.org.uk
17. Cornely OA, Maddison P, Ullmann AJ. Poster presented at ICAAC (Abstract no. A0-124)
18. Kuhn DM, Ghannoum MA. *Curr Opin Investig Drugs* 2004;5:186–97.
19. Ramage G, Martinez JP, Lopez-Ribot JL. *FEMS Yeast Res* 2006;6:979–86.
20. Kuhn DM, George T, Chandra J et al. *Antimicrob Agents Chemother* 2002;46:1773–80.
21. Chatzimoschou A, Katragkou A, Simitsopoulou E et al. 18th ECCMID Conference Proceedings 2008; P1367.
22. Katragkou A, Chatzimoschou A, Simitsopoulou E et al. *Antimicrob Agents Chemother* 2008;52:357–60.
23. Cateau E, Rodier M-H, Imbert C. *J Antimicrob Chemother* 2008;62:153–5.

Exhibition floor plan

